在5年内三阴性乳腺癌中,雄激素受体是可行的目标吗?
Marina N Sharifi1, Ruth M O'Regan2, Kari B Wisinski1
1UW Carbone Cancer Center, University of Wisconsin, Madison, Madison, WI.
Clinical breast cancer
|July 7, 2023
概括
三阴性乳腺癌 (TNBC) 是具有侵略性的,治疗选择有限的. 具有雄激素受体 (AR) 阳性的TNBC显示了针对性治疗的前景,包括雄激素信号传递抑制剂.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 内分泌学 在内分泌学.
背景情况:
- 三阴性乳腺癌 (TNBC) 在转移性环境中具有很高的复发率和不良预后.
- 目前用于TNBC的治疗方法,主要是化疗,具有有限的疗效和显著的毒性.
- 一种独特的分子亚型,光线AR (LAR) TNBC,与ER+乳腺癌具有共同的生物学特征,对雄激素信号敏感.
研究的目的:
- 审查与雄激素受体 (AR) 阳性TNBC的生物学.
- 总结AR + TNBC中雄激素向疗法的已完成和正在进行的临床试验.
- 探索安德روج因信号传递抑制剂 (ASI) 治疗AR+TNBC的潜力.
主要方法:
- 对AR+TNBC模型的临床前数据的审查.
- 对AR+ TNBC中针对雄激素向治疗的临床试验数据的分析.
- 检查针对AR+TNBC中的雄激素途径的生物学理由.
主要成果:
- AR+ TNBC 呈现出独特的分子和临床特征,包括较低的增殖率和抗化学性.
- 临床前模型表明LAR-TNBC对ASIs的敏感性.
- 临床研究正在调查ASIs在早期和转移性AR+TNBC的疗效和安全性.
结论:
- 向雄激素信号传递是AR+TNBC的一个有前途的治疗策略.
- 已证明在前列腺癌中有效的ASIs对AR+TNBC治疗具有潜力.
- 进一步的研究和临床试验对于确定ASI在管理AR+TNBC中的作用至关重要.
更多相关视频
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K